Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

Abstract: This invention provides a method for the isolation and identification of marine actinomycetes tentatively named MAR3A and MAR3B and the use of these groups as a source of new biologically active compositions including pharmaceuticals. The method includes specifics about where these microorganisms occur and their culture requirements. It also provides information describing characteristic DNA sequences that are used to identify members of this group and information demonstrating that members produce metabolites with significant activities in pharmaceutically relevant bioassays.

Abstract: A novel family of cyclic polyene natural products isolated from marine actinomycete strain CNQ140 is provided. This novel strain of actinomycetes was obtained from a previously unstudied population of marine actinomycetes that reside in sediments off La Jolla, Calif. Compounds derived from strain CNQ140 have been characterized as having a cyclic polyene-polyol structure; a molecular weight from about 996 to about 1010 in the core ring structure; and at least 58 carbons and at least 14 oxygens. The invention compounds have antitumor and/or anti-microbial activity.

Abstract: A novel family of cyclic polyene natural products isolated from marine actinomycete strain CNQ140 is provided. This novel strain of actinomycetes was obtained from a previously unstudied population of marine actinomycetes that reside in sediments off La Jolla, Calif. Compounds derived from strain CNQ140 have been characterized as having a cyclic polyene-polyol structure; a molecular weight from about 996 to about 1010 in the core ring structure; and at least 58 carbons and at least 14 oxygens. The invention compounds have antitumor and/or anti-microbial activity.

Abstract: Disclosed herein are Mactanamide compounds having the following structural formula 1

Abstract: Disclosed herein are Exumolide compounds having the following structural formula 1

Abstract: Salinamides A and B are disclosed. These two bicyclic depsipeptides are produced by fermentation of a specific marine actinomycete, a Streptomyces sp, (CNB-091) in saltwater-based media. Salinamides A and B are useful as anti-biotic and anti-inflammatory agents.

Abstract: Salinamides A and B are disclosed. These two bicyclic depsipeptides are produced by fermentation of a specific marine actinomycete, a Streptomyces sp, (CNB-091) in saltwater-based media. Salinamides A and B are useful as anti-biotic and anti-inflammatory agents.

Abstract: Methods for treating mammals to reduce pain and/or reduce inflammation are described based on administering to the mammals synthetic ether derivatives of pseudopterosin having the formula: ##STR1## wherein A is an alkyl, aryl or amide group having from 2 to 20 carbon atoms, R.sub.1, R.sub.2 and R.sub.3 are hydrogen or an acyl residue (--COR) having from 1 to 6 carbon atoms, R.sub.4 is hydrogen or --CH.sub.2 OH and R.sub.5 is a hydrocarbon having from 1 to 10 carbon atoms. Also disclosed are synthetic compositions having the above general formula which are useful in the described method.

Abstract: A cyclic heptapeptide anti-inflammatory agent named cyclomarin-A is disclosed. Cyclomarin-A is produced by a specific marine actinomycete. The cyclomarin-A producing bacterium is isolated from sediment located in marine estuaries in and around San Diego, Calif. Fermentation of the isolated bacterium in saltwater-based media produces cyclomarin-A as a secondary by-product. The cyclomarin-A is useful as an anti-inflammatory agent.

Abstract: Eleutherobin is a glycosylated diterpene which has the structural formula: ##STR1## Eleutherobin is a cytotoxic agent which is toxic to carcinoma cancer cells. Analogs of eleutherobin are also disclosed.

Abstract: A cyclic heptapeptide anti-inflammatory agent named cyclomarin-A is disclosed.Cyclomarin-A is produced by a specific marine actinomycete. The cyclomarin-A producing bacterium is isolated from sediment located in marine estuaries in and around San Diego, Calif. Fermentation of the isolated bacterium in saltwater-based media produces cyclomarin-A as a secondary by-product. The cyclomarin-A is useful as an anti-inflammatory agent.

Abstract: Methods for treating mammals to reduce pain, reduce cell proliferation and/or reduce inflammation are described based on administering to the mammals compounds having the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen or an acyl group having from 1 to 6 carbon atoms; R.sub.5 is hydrogen, CH.sub.3 or CH.sub.2 OH and R.sub.6 is a hydrocarbon having from 1 to 10 carbon atoms. Natural and synthetic 1,12-seco derivatives with similar utilities are disclosed. Natural and synthetic derivatives are also disclosed where the sugar moiety is attached at the C-10 carbon on the tricyclic diterpene moiety instead of the C-9 carbon.

Abstract: Methods for treating mammals to reduce pain, reduce cell proliferation and/or reduce inflammation are described based on administering to the mammals compounds having the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen or an acyl residue hydrocarbon having from 1 to 6 carbon atoms, R.sub.5 is hydrogen or CH.sub.2 OH and R.sub.6 is a functionalized hydrocarbon having from 1 to 10 carbon atoms. Natural and synthetic 1,12-seco derivatives of pseudopterosin with similar utilities are disclosed. Synthetic compositions having the above general formula which are useful in the method are disclosed.